Merus annonce ses résultats financiers pour le premier trimestre 2024 et fait le point sur ses activités
May 10, 2024 12:36 ET
|
Merus N.V.
Données cliniques intermédiaires initiales concernant le pétosemtamab en association avec le pembrolizumab en traitement de 1re ligne du CETC présentées lors du congrès annuel de l’ASCO 2024 ;...
Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 10, 2024 07:00 ET
|
Akero Therapeutics Inc.
-- Statistically significant week 96 results from the Phase 2b HARMONY study of EFX in patients with pre-cirrhotic MASH reported during the first quarter of 2024 -- -- Phase 3 SYNCHRONY Histology and...
Kronos Bio Reports First-Quarter 2024 Financial Results
May 09, 2024 16:05 ET
|
Kronos Bio, Inc.
— $152.0 million cash runway into the second half of 2026 — — A study update on KB-0742-1001 will be presented at the upcoming American Society of Clinical Oncology (ASCO); expansion cohorts at new...
One Stop Systems Reports Q1 2024 Results
May 09, 2024 16:04 ET
|
One Stop Systems, Inc.
ESCONDIDO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- One Stop Systems, Inc. ("OSS" or the "Company") (Nasdaq: OSS), a leader in rugged Enterprise Class compute for artificial intelligence (AI),...
Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
May 09, 2024 16:01 ET
|
Iovance Biotherapeutics, Inc.
Strong Momentum for Amtagvi™ (Lifileucel) U.S. Launch Following U.S. Food and Drug Administration (FDA) Approval 100+ Amtagvi Patients Enrolled Across More Than 40 Current Authorized Treatment...
Critical Response Group Partners with McCarthy Capital to Accelerate Growth
May 09, 2024 11:01 ET
|
Critical Response Group
Critical Response Group Partners with McCarthy Capital to Accelerate Growth
Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
May 09, 2024 08:00 ET
|
Vera Therapeutics
Presented positive 72-week data from the Phase 2b ORIGIN clinical trial, setting a new standard in IgAN with no loss of kidney function over the duration of treatmentTopline 96-week data from ORIGIN 2...
Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients
May 09, 2024 08:00 ET
|
Akoya Biosciences, Inc.
MARLBOROUGH, Mass. and FRANKFURT, Germany, May 09, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, and NeraCare, a leading developer of laboratory...
XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities
May 09, 2024 07:30 ET
|
XOMA Corporation
Earned $9 million milestone upon U.S. Food and Drug Administration’s approval of Day One’s OJEMDA™ (tovorafenib); XOMA is entitled to receive a mid-single digit royalty on OJEMDA™ sales Acquired...
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
May 09, 2024 07:00 ET
|
Larimar Therapeutics
First patient dosed in open label extension (OLE) study with 25 mg daily dosing of nomlabofusp; interim data on track for Q4 2024 Positive top-line Phase 2 dose exploration study data demonstrated...